Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/25/16 → 10/24/18 |
Funding
- G1 Therapeutics Incorporated: $10,685.00
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy
- Mullett, Timothy (PI)